CRBU Latest News, Press Relases and Analysis

All

Press Releases

18 days ago - By: Zacks Investment Research - Mentions: DARE

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates

18 days ago - By: Caribou Biosciences, Inc.

Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

20 days ago - By: Zacks Investment Research - Mentions: SEPN

Septerna, Inc. (SEPN) Reports Q3 Loss, Misses Revenue Estimates

a month ago - By: Caribou Biosciences, Inc.

Caribou Biosciences to Participate in Upcoming Investor Conferences

a month ago - By: Caribou Biosciences, Inc.

Caribou Biosciences to Participate in Upcoming Investor Conferences

a month ago - By: Stocktwits - Mentions: VXF CNCR

Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments

a month ago - By: Benzinga

Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today?

a month ago - By: Benzinga - Mentions: IMRN CUE LQDA TCRX ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

a month ago - By: Caribou Biosciences, Inc.

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

a month ago - By: Caribou Biosciences, Inc.

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

a month ago - By: Caribou Biosciences, Inc.

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

a month ago - By: Caribou Biosciences, Inc.

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

a month ago - By: Caribou Biosciences, Inc.

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

3 months ago - By: Caribou Biosciences, Inc.

Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

3 months ago - By: Caribou Biosciences, Inc.

Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

4 months ago - By: Caribou Biosciences, Inc.

Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Bragar Eagel & Squire

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

6 months ago - By: Caribou Biosciences, Inc.

Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

6 months ago - By: Caribou Biosciences, Inc.

Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

7 months ago - By: Zacks Investment Research - Mentions: CTMX

Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates

7 months ago - By: Caribou Biosciences, Inc.

Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

7 months ago - By: Caribou Biosciences, Inc.

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

7 months ago - By: Caribou Biosciences, Inc.

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

7 months ago - By: Zacks Investment Research - Mentions: CLSD

Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know

7 months ago - By: Zacks Investment Research - Mentions: AMGN

Will Caribou Biosciences, Inc. (CRBU) Report Negative Q1 Earnings? What You Should Know

7 months ago - By: Caribou Biosciences, Inc.

Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

7 months ago - By: Caribou Biosciences, Inc.

Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

9 months ago - By: Caribou Biosciences, Inc.

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

9 months ago - By: Caribou Biosciences, Inc.

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

9 months ago - By: Bragar Eagel & Squire

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

9 months ago - By: THE ROSEN LAW FIRM, P. A.

CRBU Deadline: CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit

9 months ago - By: The Gross Law Firm

Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU

9 months ago - By: Levi & Korsinsky, LLP

February 24, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against CRBU

9 months ago - By: Faruqi & Faruqi, LLP

CARIBOU BIOSCIENCES INC (CRBU) Stock News

CRBU Latest News, Press Relases and Analysis

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates

Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Septerna, Inc. (SEPN) Reports Q3 Loss, Misses Revenue Estimates

Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments

Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today?

12 Health Care Stocks Moving In Monday's Pre-Market Session

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates

Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know

Will Caribou Biosciences, Inc. (CRBU) Report Negative Q1 Earnings? What You Should Know

Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

CRBU Deadline: CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit

Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU

February 24, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against CRBU

Faruqi & Faruqi Reminds Caribou Biosciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 24, 2025 - CRBU